144 related articles for article (PubMed ID: 37925045)
1. Lipoxin-mediated signaling: ALX/FPR2 interaction and beyond.
Sánchez-García S; Jaén RI; Fernández-Velasco M; Delgado C; Boscá L; Prieto P
Pharmacol Res; 2023 Nov; 197():106982. PubMed ID: 37925045
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation of the formyl peptide receptor 2 gene.
Simiele F; Recchiuti A; Patruno S; Plebani R; Pierdomenico AM; Codagnone M; Romano M
Biochim Biophys Acta; 2016 Oct; 1859(10):1252-8. PubMed ID: 27424221
[TBL] [Abstract][Full Text] [Related]
3. Lipoxin A
Gaudin A; Tolar M; Peters OA
Sci Rep; 2018 Jun; 8(1):8921. PubMed ID: 29892010
[TBL] [Abstract][Full Text] [Related]
4. Treating neutrophilic inflammation in COPD by targeting ALX/FPR2 resolution pathways.
Bozinovski S; Anthony D; Anderson GP; Irving LB; Levy BD; Vlahos R
Pharmacol Ther; 2013 Dec; 140(3):280-9. PubMed ID: 23880288
[TBL] [Abstract][Full Text] [Related]
5. Lack of resolution sensor drives age-related cardiometabolic and cardiorenal defects and impedes inflammation-resolution in heart failure.
Tourki B; Kain V; Pullen AB; Norris PC; Patel N; Arora P; Leroy X; Serhan CN; Halade GV
Mol Metab; 2020 Jan; 31():138-149. PubMed ID: 31918915
[TBL] [Abstract][Full Text] [Related]
6. Heterologously expressed formyl peptide receptor 2 (FPR2/ALX) does not respond to lipoxin A₄.
Hanson J; Ferreirós N; Pirotte B; Geisslinger G; Offermanns S
Biochem Pharmacol; 2013 Jun; 85(12):1795-802. PubMed ID: 23643932
[TBL] [Abstract][Full Text] [Related]
7. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo.
Chiang N; Serhan CN; Dahlén SE; Drazen JM; Hay DW; Rovati GE; Shimizu T; Yokomizo T; Brink C
Pharmacol Rev; 2006 Sep; 58(3):463-87. PubMed ID: 16968948
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-181b regulates ALX/FPR2 receptor expression and proresolution signaling in human macrophages.
Pierdomenico AM; Recchiuti A; Simiele F; Codagnone M; Mari VC; Davì G; Romano M
J Biol Chem; 2015 Feb; 290(6):3592-600. PubMed ID: 25505240
[TBL] [Abstract][Full Text] [Related]
9. Resolvin D1 inhibits TGF-β1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32.
Lee HJ; Park MK; Lee EJ; Lee CH
Int J Biochem Cell Biol; 2013 Dec; 45(12):2801-7. PubMed ID: 24120851
[TBL] [Abstract][Full Text] [Related]
10. Airway lipoxin A4/formyl peptide receptor 2-lipoxin receptor levels in pediatric patients with severe asthma.
Gagliardo R; Gras D; La Grutta S; Chanez P; Di Sano C; Albano GD; Vachier I; Montalbano AM; Anzalone G; Bonanno A; Riccobono L; Gjomarkaj M; Profita M
J Allergy Clin Immunol; 2016 Jun; 137(6):1796-1806. PubMed ID: 26971688
[TBL] [Abstract][Full Text] [Related]
11. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis.
Maderna P; Cottell DC; Toivonen T; Dufton N; Dalli J; Perretti M; Godson C
FASEB J; 2010 Nov; 24(11):4240-9. PubMed ID: 20570963
[TBL] [Abstract][Full Text] [Related]
12. Lack of activity of 15-epi-lipoxin A₄ on FPR2/ALX and CysLT1 receptors in interleukin-8-driven human neutrophil function.
Planagumà A; Domenech T; Jover I; Ramos I; Sentellas S; Malhotra R; Miralpeix M
Clin Exp Immunol; 2013 Aug; 173(2):298-309. PubMed ID: 23607720
[TBL] [Abstract][Full Text] [Related]
13. A role for lipoxin A₄ as an anti-inflammatory mediator in the human endometrium.
Macdonald LJ; Boddy SC; Denison FC; Sales KJ; Jabbour HN
Reproduction; 2011 Aug; 142(2):345-52. PubMed ID: 21555360
[TBL] [Abstract][Full Text] [Related]
14. Dual modulation of formyl peptide receptor 2 by aspirin-triggered lipoxin contributes to its anti-inflammatory activity.
Ge Y; Zhang S; Wang J; Xia F; Wan JB; Lu J; Ye RD
FASEB J; 2020 May; 34(5):6920-6933. PubMed ID: 32239559
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.
Maciuszek M; Cacace A; Brennan E; Godson C; Chapman TM
Eur J Med Chem; 2021 Mar; 213():113167. PubMed ID: 33486199
[TBL] [Abstract][Full Text] [Related]
16. Lipoxin A₄ modulates adaptive immunity by decreasing memory B-cell responses via an ALX/FPR2-dependent mechanism.
Ramon S; Bancos S; Serhan CN; Phipps RP
Eur J Immunol; 2014 Feb; 44(2):357-69. PubMed ID: 24166736
[TBL] [Abstract][Full Text] [Related]
17. Macrophage sub-populations and the lipoxin A4 receptor implicate active inflammation during equine tendon repair.
Dakin SG; Werling D; Hibbert A; Abayasekara DR; Young NJ; Smith RK; Dudhia J
PLoS One; 2012; 7(2):e32333. PubMed ID: 22384219
[TBL] [Abstract][Full Text] [Related]
18. Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation.
Parkinson JF
Inflamm Allergy Drug Targets; 2006 Apr; 5(2):91-106. PubMed ID: 16613568
[TBL] [Abstract][Full Text] [Related]
19. Inflamm-aging and arachadonic acid metabolite differences with stage of tendon disease.
Dakin SG; Dudhia J; Werling NJ; Werling D; Abayasekara DR; Smith RK
PLoS One; 2012; 7(11):e48978. PubMed ID: 23155437
[TBL] [Abstract][Full Text] [Related]
20. Lipoxin Signaling in Murine Lung Host Responses to Cryptococcus neoformans Infection.
Colby JK; Gott KM; Wilder JA; Levy BD
Am J Respir Cell Mol Biol; 2016 Jan; 54(1):25-33. PubMed ID: 26039320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]